The prevalence ofmultiple sclerosis in the Rochdale Metropolitan Borough in the north east of Greater Manchester has been established. Case ascertainment was partly prospective via a neurological register from 1979 and by contact with general practitioners, therapists, and social services. On prevalence day, 1 January 1989, 254 patients with multiple sclerosis were living in Rochdale. The overall prevalence was 122/100 000 population and 96/100 000 population for probable cases only. The peak rate for women aged 35 to 44 years was 4371100 000 population and for men aged 45 to 54 years 221/100 000. Familial multiple sclerosis was present in 10-8% of families. In this, the first study in north west England, the prevalence of multiple sclerosis in Rochdale is similar to that in southern England and Wales but lower than that in Scotland.
Patients and methods The approval of the district ethics committee was obtained. We sought to establish the point prevalence of multiple sclerosis in Rochdale on 1 January 1989. Since the appointment of one of us (DIS) in 1979 as neurologist responsible for Rochdale district, a diagnostic index of all neurology patients seen has been kept in the subregional neurological centre at North Manchester General Hospital. Further patients were located through identification by one of us (DIS) during the course of the study and through voluntary organisations, the Social Services register of disabled people, hospital activity analysis, and other health service sources (notably occupational therapists, speech therapists, chiropodists), and the younger disabled unit. Residents with multiple sclerosis in the Leonard Cheshire Home were only accepted if their previous residence was within the study area. These accumulated data were then sent to the appropriate general practitioner who identified some additional patients and indicated who was alive and living in the area on prevalence day, 1 January 1989. A proforma was established for each patient and in many cases adequate data were obtained from the existing neurological records. All general practices were visited and additional information obtained, when relevant, from 90 patients' records. A few patients were visited in their homes with the permission of the general practitioner.
Classification was according to Allison and Miller14 and the Poser diagnostic criteria but without adherence to the upper age limit of 59 in the second.'5 To allow comparison of prevalence in populations with different age and sex Shepherd, Summers Annual incidence rates calculated from date of onset of the disease in the 254 prevalent patients were 5 4/100 000 during the most recent five year period and 5 4, 4.3, 4-1, and 2 4/100 000 during the four previous five year periods (with the most recent quoted first). Table 2 provides a summary of the findings in the present survey in comparison with eight previous prevalence surveys in large population areas in the United Kingdom over the past 20 years. For the purposes of comparison, the early probable and latent group in the first north east Scotland survey2 has been combined with the probable group. The standardised prevalence ratio (SPR) allows comparison between surveys in populations which have different age/sex distributions. Sex ratio (F:M) Twenty seven patients in the study had another first degree relative affected and in four instances, the second relative was in this survey. There were eight instances of parent/child relationship and nine of affected siblings. In three families more than one relative was affected; thus 10-8% of families (27 out of 250) had a positive family history. In this survey 122 patients (48.2%) were born within the study area, a further 84 (33 2%) within the north west of England, and only five were born outside the United Kingdom.
Discussion
We think that our estimate of prevalence is unlikely to be increased by resurveying. Firstly, this was predominantly a prospective study based on the planned accumulation of data on all patients (inpatients and outpatients, ward referrals, domiciliary, and private patients) by one of us (DIS) from 1979 and secondly, over the succeeding three years, we have only located a further 11 patients who diagnostically would have been eligible for inclusion on 1 January 1989.
In Rochdale the mean age of onset was slightly later and the mean duration slightly shorter than in other comparable surveys (table 2). The incidence estimate for Rochdale was comparable with those for other surveys in England and Wales. The familial occurrence of 10-8% exceeded the figure of 9-8% for the second north east Scotland study'7 but is less than the 17% recorded in a Canadian study. '8 Repeating prevalence studies in the same population in north east Scotland3 4 and in Cambridge'9 has shown a higher prevalence on resurveying. Explanations proposed include improved case ascertainment, changes in survey methodology, and changes in the population age structure. In south east Wales, however, a second prevalence study after three years did not show an increase in prevalence. 20 The difference in prevalence of multiple sclerosis between Scotland and other parts of the United Kingdom is well known. Evidence from mortality statistics suggests that this gradient may be declining.2' The standardised prevalence ratio (SPR) provides the most appropriate means of comparing surveys in different populations. Using this measure, the prevalence estimate for Rochdale (143) is similar to those obtained in south east Wales and in the second Cambridge survey-in other words, similar to the highest estimates obtained from surveys in the southern part of the United Kingdom. There is no significant difference between the SPR for Rochdale and the SPR for the southern United Kingdom surveys.
We conclude that this first study in north west England shows the prevalence of multiple sclerosis to be similar to that in southern England and Wales but lower than that in Scotland.
